DGAP-News: Evotec SE / Key word(s): Miscellaneous 
Just - Evotec Biologics Expands Contract with the Department of Defense for Manufacturing of Monoclonal Antibodies 
2021-01-27 / 07:30 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
  . JUST - EVOTEC BIOLOGICS WILL MANUFACTURE ANTI-SARS-COV-2 AND OTHER ANTIBODIES AT ITS J.POD^(R) MANUFACTURING 
    FACILITY 
  . ACCESS TO MANUFACTURING CAPACITY OVER A PERIOD OF 7 YEARS 
Hamburg, Germany, 27 January 2021: 
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the U.S. Department of 
Defense ("DOD") awarded its Seattle, Washington-based subsidiary, Just - Evotec Biologics, Inc., an agreement worth 
USD28.6 million for the production of monoclonal antibodies ("mAbs") for use in the development of a treatment and/or 
prophylaxis for COVID-19. 
The DOD's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense ("JPEO-CBRND") is 
executing this effort in coordination with the Office of the Assistant Secretary of Defense for Health Affairs ("OASD 
(HA)") and the Defense Health Agency ("DHA"). 
Under the agreement, the DOD will have access to pivotal manufacturing capacity for anti-SARS-CoV-2 mAbs and priority 
access to future biomanufacturing capacity over a period of seven years in the soon-to-be-completed J.POD^(R) facility 
in Redmond, Washington. The agreement represents the continuation of DOD's collaboration with Just - Evotec Biologics. 
The collaboration started in July of 2020 and involved the selection of anti-SARS-CoV2 mAbs, resulting in rapid process 
development and manufacture of high yielding mAbs against SARS-CoV-2. 
Dr James Thomas, Executive Vice President, Global Head Biotherapeutics at Just - Evotec Biologics, said: "It is an 
honour to extend our relationship with the DOD in response to the COVID-19 pandemic. Our technologies and expertise in 
molecule optimization, process and product development, and manufacturing are well suited to rapidly support the DOD's 
needs for COVID-19 and other infectious disease threats." 
Dr Craig Johnstone, Chief Operating Officer of Evotec, said: "Evotec continues to be committed to the global fight 
against infectious diseases such as COVID-19 and actively promotes future pandemic preparedness by adding novel 
therapeutic antibodies to our toolbox. In our collaboration with the U.S. Department of Defense we were able to select 
anti-SARS-CoV-2 mAbs and develop a high-yielding production process in as little as six months. We are honoured to 
continue with the production of the mAb as one of the Advanced Defense service providers to the DOD." 
ABOUT JUST - EVOTEC BIOLOGICS 
Just - Evotec Biologics wholly owned by Evotec SE is a unique platform company that integrates the design, engineering, 
development, and manufacture of biologics. With deep experience in the fields of protein, process and manufacturing 
sciences, the Just team came together to solve the scientific and technical hurdles that block access to life-changing 
protein therapeutics; from the design of therapeutic molecules to the design of the manufacturing plants used to 
produce them. Our focus is to create access and value for a global market through scientific and technological 
innovation. Learn more at www.just.bio. 
ABOUT EVOTEC SE 
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative 
product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and 
venture capitalists. We operate worldwide and our more than 3,500 employees provide the highest quality stand-alone and 
integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the 
industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has 
established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies 
as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and 
complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare 
diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of more than 100 co-owned 
product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple 
long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo 
Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us 
on Twitter @Evotec. 
FORWARD-LOOKING STATEMENTS 
Information set forth in this press release contains forward-looking statements, which involve a number of risks and 
uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this 
press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of 
risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ 
materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or 
undertaking to release publicly any updates or revisions to any such statements to reflect any change in our 
expectations or any change in events, conditions or circumstances on which any such statement is based. 
Media Contact Evotec SE: 
Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255, 
gabriele.hansen@evotec.com 
IR Contact Evotec SE: 
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com 
=---------------------------------------------------------------------------------------------------------------------- 
2021-01-27 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Evotec SE 
              Manfred Eigen Campus / Essener Bogen 7 
              22419 Hamburg 
              Germany 
Phone:        +49 (0)40 560 81-0 
Fax:          +49 (0)40 560 81-222 
E-mail:       info@evotec.com 
Internet:     www.evotec.com 
ISIN:         DE0005664809 
WKN:          566480 
Indices:      MDAX, TecDAX 
Listed:       Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1163524 
 
End of News   DGAP News Service 
=------------ 

1163524 2021-01-27

(END) Dow Jones Newswires

January 27, 2021 01:31 ET (06:31 GMT)